Iron and Zinc Supplementation Does Not Impact Urinary Arsenic Excretion in Mexican School Children - 14/12/17
Abstract |
Objective |
To examine the role of iron and zinc in arsenic excretion and metabolism in children.
Study design |
An analysis of urinary arsenic (UAs) concentrations from a double-blind randomized trial originally testing the efficacy of iron and zinc for lowering blood lead levels in children. A 2 × 2 factorial design was used, with children randomized individually, stratified by sex and classroom, to receive 30 mg ferrous fumarate (n = 148), 30 mg zinc oxide (n = 144), iron and zinc together (n = 148), or placebo (n = 151). Of the 602 children enrolled, 527 completed the 6-month treatment, and 485 had both baseline and final UAs values. The baseline total UAs concentration ranged from 3.2 to 215.9 µg/L.
Results |
At baseline, children in the highest tertile of serum ferritin concentration had higher excretion of dimethylarsinic acid (DMA; 1.93 ± 0.86%; P < .05), but lower excretion of monomethylarsonic acid (-0.91 ± 0.39%; P < .05), compared with children in the lowest tertile. In an intention-to-treat analysis, iron had no effect on arsenic methylation or UAs excretion, but children receiving zinc had lower %DMA in urine (-1.7 ± 0.8; P < .05).
Conclusions |
Iron and zinc status are not related to arsenic metabolism in children, and supplementation with these minerals has limited application in lowering arsenic concentrations.
Trial registration |
ClinicalTrials.gov: NCT02346188.
Le texte complet de cet article est disponible en PDF.Keywords : urinary arsenic, methylated arsenic, iron-zinc supplementation, child, Mexico
Abbreviations : BLL, BMI, DMA, Hb, iAs, ID, MMA, SES, UAs
Plan
Funded by the Spencer Foundation. The authors declare no conflicts of interest. |
Vol 185
P. 205 - juin 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?